The release of interchangeable Humira biosimilars is increasing accessibility to effective rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis treatments while reducing costs.  

This is a win-win situation for patients, healthcare providers, and payers, as pricing for these products falls due to increasing competition from biosimilars.  

The Rise of Interchangeable Humira Biosimilars

On July 1, numerous Humira biosimilars hit the U.S. market. In this new era, FDA-approved Humira biosimilars have driven more rapid and efficient conversion to lower-cost alternatives. Cyltezo®, a Humira biosimilar developed by Boehringer Ingelheim, is the first interchangeable Humira biosimilar approved by the FDA. This is a significant milestone because the FDA’s interchangeability designation allows pharmacists to substitute a biosimilar for the reference product. Pharmacists can substitute for a biosimilar without a specific prescription unless prohibited by law.  

Humira biosimilars launched this summer include Pfizer’s Abrilada, Celltrion’s Yuflyma®, Samsung Bioepis/Organon’s Hadlima, and Sandoz’s Hyrimoz®. Amgen’s Amjevita™ is approved and available as an interchangeable, as-is. AVT02, another interchangeable Humira biosimilar released in July, is also approved in the European Union, Australia, Canada, and the United Kingdom. 

Factors Influencing Payer and PBM Decisions

Payers and pharmacy benefit managers continue to consider various factors when deciding which Humira biosimilars to add to their formularies. These factors include interchangeability, formulation differences, the manufacturer’s ability to meet demand, and pricing strategy. Among these, pricing will be the most crucial factor. As a trusted partner committed to providing cost-effective solutions for our clients, we are closely watching developments in this area and are committed to bringing forth coverage strategies that balance access and cost. 

About Serve You Rx   
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for over 36 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.

Read more about the Humira biosimilar launch here: Humira Users: Help is on the Way